在豚鼠模型中测试的近视控制生物工程方法
本研究在7日龄豚鼠形觉剥夺模型中,于眼球后极部行Tenon囊下注射透明质酸水凝胶或缓冲液,继续形觉剥夺3周。水凝胶组与假手术组均较单纯形觉剥夺组显著减少眼轴延长和近视进展,眼压、视力及闪光视网膜电图未见显著异常。
要点
- 水凝胶组与假手术组均较单纯形觉剥夺组显著减少眼轴延长和近视进展。
- 治疗眼眼压、视力及闪光视网膜电图与对侧对照眼无显著差异。
- 两种手术组均可见Tenon囊增厚,水凝胶植入物内有大量细胞迁移。
核心结论
- Tenon囊下注射水凝胶或缓冲液均抑制豚鼠近视进展,对眼健康无不良影响。
- 缓冲液的意外效应有待进一步研究,可能成为新型近视控制疗法。
- 水凝胶植入物支持显著细胞浸润,进一步证明其生物相容性,有望作为药物和细胞递送工具。
研究设计与样本
- 研究使用丙烯酸化透明质酸与偶联细胞结合肽及酶可降解交联剂合成的水凝胶。
- 7日龄豚鼠先用弥散器行形觉剥夺1周,分为单纯形觉剥夺对照组、水凝胶注射组和缓冲液注射(假手术)组。
- 水凝胶或缓冲液注射于眼球后极部Tenon囊下,随后继续形觉剥夺3周。
- 通过眼轴长度和屈光不正评估治疗效果,通过眼压、视力、闪光视网膜电图和组织学评估安全性。
主要发现
- 眼轴长度眼间差(治疗眼减对照眼)净变化:水凝胶组0.04±0.06 mm、假手术组0.02±0.09 mm、单纯形觉剥夺组0.24±0.08 mm(P=0.0006)。
- 水凝胶组和假手术组均较单纯形觉剥夺组显著减少眼轴延长和近视进展。
- 治疗眼眼压、视力及闪光视网膜电图与对侧对照眼无显著差异。
- 植入物内可见大量细胞迁移,两种手术组均可见明显的Tenon囊增厚。
局限性
- 缓冲液注射的意外效应有待进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the biocompatibility of an injectable hydrogel and its ability to control myopia progression in guinea pigs. METHODS: The study used a hydrogel synthesized from acrylated hyaluronic acid with a conjugated cell-binding peptide and enzymatically degradable crosslinker. Seven-day-old guinea pigs were first form deprived (FD) with diffusers for 1 week. One group was kept as an FD-only control; two groups received a sub-Tenon's capsule injection of either hydrogel or buffer (sham surgery) at the posterior pole of the eye. Form deprivation treatments were then continued for 3 additional weeks. Treatment effects were evaluated in terms of ocular axial length and refractive error. Safety was evaluated via intraocular pressure (IOP), visual acuity, flash electroretinograms (ERG), and histology. RESULTS: Both hydrogel and sham surgery groups showed significantly reduced axial elongation and myopia progression compared to the FD-only group. For axial lengths, net changes in interocular difference (treated minus control) were 0.04 ± 0.06, 0.02 ± 0.09, and 0.24 ± 0.08 mm for hydrogel, sham, and FD-only groups, respectively (P = 0.0006). Intraocular pressures, visual acuities, and ERGs of treated eyes were not significantly different from contralateral controls. Extensive cell migration into the implants was evident. Both surgery groups showed noticeable Tenon's capsule thickening. CONCLUSIONS: Sub-Tenon's capsule injections of both hydrogel and buffer inhibited myopia progression, with no adverse effects on ocular health. The latter unexpected effect warrants further investigation as a potential novel myopia control therapy. That the hydrogel implant supported significant cell infiltration offers further proof of its biocompatibility, with potential application as a tool for drug and cell delivery.
引用
- Garcia MB, Jha AK, Healy KE, et al. A Bioengineering Approach to Myopia Control Tested in a Guinea Pig Model. Invest Ophthalmol Vis Sci. 2017. PMID: 28358959. doi:10.1167/iovs.16-20694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。